Turkish oncologists determine eligibility for targeted therapy through comprehensive genomic profiling and multidisciplinary tumor board reviews. They use next-generation sequencing to identify driver mutations like EGFR, ALK, or BRAF. Doctors confirm these actionable targets to match patients with specific precision drugs.
- Molecular testing: Next-generation sequencing maps tumor genetic profiles to detect specific actionable mutations.
- Biomarker identification: Tests identify proteins like ROS1 or HER2 that drive cancer cell growth.
- Multidisciplinary review: Tumor boards analyze NGS results, imaging, and patient history for approval.
- Clinical assessment: Doctors evaluate performance status and organ function to ensure treatment safety.
Bookimed Expert Insight: Turkish oncology centers often perform complex genomic testing in-house. This allows specialists like Dr. Bulent Karagoz at Anadolu Medical Center to receive results within 14 days. This speed is critical for patients with aggressive tumors needing rapid treatment changes. Dr. Yesim Yildirim, an ESMO-certified professor, frequently utilizes international clinical study data to personalize these choices for her patients.
Patient Consensus: Patients note that bringing previous biopsy results and imaging can speed up the eligibility process. Many felt reassured when tumor boards collectively reviewed their cases to confirm the best drug match. They also found the 24/7 coordinator support helpful for navigating fast-tracked diagnostic testing schedules.
